sj-docx-1-opp-10.1177_10781552211052535 - Supplemental material for Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions

MLA

Del Rosario García, Betel, et al. Sj-Docx-1-Opp-10.1177_10781552211052535 - Supplemental Material for Imatinib Plasma Levels in Patients with Chronic Myeloid Leukaemia under Routine Clinical Practice Conditions. Jan. 2022. EBSCOhost, https://doi.org/10.25384/sage.21713855.

APA

Del Rosario García, B., González García, I., Viña Romero, M. M., González García, J., Ramos Díaz, R., Mourani Padrón, I., Lakhwani Lakhwani, S., Nazco Casariego, G. J., & Gutiérrez Nicolás, F. (2022). sj-docx-1-opp-10.1177_10781552211052535 - Supplemental material for Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions. https://doi.org/10.25384/sage.21713855

Chicago

Del Rosario García, Betel, Iris González García, María Micaela Viña Romero, Jonathan González García, Ruth Ramos Díaz, Ivette Mourani Padrón, Sunil Lakhwani Lakhwani, Gloria Julia Nazco Casariego, and Fernando Gutiérrez Nicolás. 2022. “Sj-Docx-1-Opp-10.1177_10781552211052535 - Supplemental Material for Imatinib Plasma Levels in Patients with Chronic Myeloid Leukaemia under Routine Clinical Practice Conditions,” January. doi:10.25384/sage.21713855.